Anju Ghangurde
Executive Editor, APAC
Anju has been a journalist since 1993 including stints at India's leading financial dailies. She covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Latest From Anju Ghangurde
Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
Glenmark Seeks To Revive US Momentum After Earnings 'Aberration'
Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.
Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling
In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.
Glenmark Seeks To Revive US Momentum After Earnings 'Aberration'
Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.
Syngene Eyes Sweet Spot As New Modalities Hog Limelight
Syngene’s CEO discusses its work in ADC development and trends in the CRDMO space as US biotechs navigate a funding squeeze and manufacturing opportunities loom in areas like GLP- 1 receptor agonists.
Syngene CEO On Sub-Dynamics As US Biotech Funding Finds New Normal, ADC Capabilities
Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and partnerships with big pharma are some of the other topics the former AstraZeneca executive discussed.